Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Irina, Lyadova Vladimirovna ^a   Sosunova, Ekaterina ^a   Nikolaev, Alexander ^a   Nenasheva, Tatiana ^a  

^a CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MESENCHYMAL STEM CELL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MESENCHYMAL STROMA CELL; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; OXIDATION REDUCTION REACTION;

BIOLOGICAL MARKER; CYTOKINE;

ANIMALS; BIOMARKERS; CELL DIFFERENTIATION; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTE SUBSETS; MESENCHYMAL STROMAL CELLS; MYELOID-DERIVED SUPPRESSOR CELLS; OXIDATION-REDUCTION;

EID: 84982182028     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/7121580     Document Type: Review

References (231)

1. D. A. A. Vignali, L. W. Collison, and C. J. Workman, "How regulatory T cells work, " Nature Reviews Immunology, vol. 8, pp. 523-532, 2008.
2. C. Benoist and D. Mathis, "Treg cells, life history, and diversity, " Cold Spring Harbor Perspectives in Biology, vol. 4, no. 9, Article ID a007021, 2012.
3. J. Durand and E. Chiffoleau, "B cells with regulatory properties in transplantation tolerance, " World Journal of Transplantation, vol. 5, no. 4, pp. 196-208, 2015.
4. J. Liu, D. Chen, G. D. Nie, and Z. Dai, "CD8+CD122+ Tcells: a newly emerging regulator with central memory cell phenotypes, " Frontiers in Immunology, vol. 6, article 494, 2015.
5. M. Najar, G. Raicevic, H. Fayyad-Kazan, D. Bron, M. Toungouz, and L. Lagneaux, "Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells, " Cytotherapy, vol. 18, no. 2, pp. 160-171, 2016.
6. D. I. Gabrilovich and S. Nagaraj, "Myeloid-derived suppressor cells as regulators of the immune system, " Nature Reviews Immunology, vol. 9, no. 3, pp. 162-174, 2009.
7. J. D. Glenn and K. A. Whartenby, "Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy, " World Journal of Stem Cells, vol. 6, no. 5, pp. 526-539, 2014.
8. F. Dazzi, R. Ramasamy, S. Glennie, S. P. Jones, and I. Roberts, "The role of mesenchymal stem cells in haemopoiesis, " Blood Reviews, vol. 20, no. 3, pp. 161-171, 2006.
9. A. Ehninger and A. Trumpp, "The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in, " Journal of Experimental Medicine, vol. 208, no. 3, pp. 421-428, 2011.
10. J. Isern, B. Martín-Antonio, R. Ghazanfari et al., "Self-renewing human bone marrow mesenspheres promote hematopoietic stem cell expansion, " Cell Reports, vol. 3, no. 5, pp. 1714-1724, 2013.
11. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, " Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
12. S. A. Boxall and E. Jones, "Markers for characterization of bone marrow multipotential stromal cells, " Stem Cells International, vol. 2012, Article ID975871, 12 pages, 2012.
13. Y. Mabuchi, D. D. Houlihan, C. Akazawa, H. Okano, and Y. Matsuzaki, "Prospective isolation of murine and human bone marrow mesenchymal stem cells based on surface markers, " Stem Cells International, vol. 2013, Article ID 507301, 7 pages, 2013.
14. M. Di Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, " Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
15. P. Mattar and K. Bieback, "Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissuemesenchymal stromal cells, " Frontiers in Immunology, vol. 6, article 560, 2015.
16. T. Condamine and D. I. Gabrilovich, "Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function, " Trends in Immunology, vol. 32, no. 1, pp. 19-25, 2011.
17. S. Ostrand-Rosenberg and P. Sinha, "Myeloid-derived suppressor cells: linking inflammation and cancer, " The Journal of Immunology, vol. 182, no. 8, pp. 4499-4506, 2009.
18. A. G. Cuenca, M. J. Delano, K. M. Kelly-Scumpia et al., "A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma, " Molecular Medicine, vol. 17, no. 3-4, pp. 281-292, 2011.
19. E. N. Tsiganov, E. M. Verbina, T. V. Radaeva et al., "Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice, " Journal of Immunology, vol. 192, no. 10, pp. 4718-4727, 2014.
20. L. A. Haile, J. Gamrekelashvili, M. P. Manns, F. Korangy, and T. F. Greten, "CD49d is a new marker for distinct myeloidderived suppressor cell subpopulations in mice, " The Journal of Immunology, vol. 185, no. 1, pp. 203-210, 2010.
21. N. Dilek, R. Vuillefroy de Silly, G. Blancho, and B. Vanhove, "Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance, " Frontiers in Immunology, vol. 3, article 208, 2012.
22. D. Marvel and D. I. Gabrilovich, "Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected, " The Journal of Clinical Investigation, vol. 125, no. 9, pp. 3356-3364, 2015.
23. M. L. Ortiz, L. Lu, I. Ramachandran, and D. I. Gabrilovich, "Myeloid-derived suppressor cells in the development of lung cancer, " Cancer Immunology Research, vol. 2, no. 1, pp. 50-58, 2014.
24. J. G. Cripps and J. D. Gorham, "MDSC in autoimmunity, " International Immunopharmacology, vol. 11, no. 7, pp. 789-793, 2011.
25. J. A. Van Ginderachter, A. Beschin, P. D. Baetselier, and G. Raes, "Myeloid-derived suppressor cells in parasitic infections, " European Journal of Immunology, vol. 40, no. 11, pp. 2976-2985, 2010.
26. O. Goño, P. Alcaide, and M. Fresno, "Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1+)CD11b+ immature myeloid suppressor cells, " International Immunology, vol. 14, no. 10, pp. 1125-1134, 2002.
27. H. Soliman, M. Mediavilla-Varela, and S. Antonia, "Indoleamine 2, 3-dioxygenase is it an immune suppressor" Cancer Journal, vol. 16, no. 4, pp. 354-359, 2010.
28. D. H. Munn andA. L. Mellor, "Indoleamine 2, 3 dioxygenase and metabolic control of immune responses, " Trends in Immunology, vol. 34, no. 3, pp. 137-143, 2013.
29. M. D. Sharma, D.-Y. Hou, Y. Liu et al., "Indoleamine 2, 3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes, " Blood, vol. 113, no. 24, pp. 6102-6111, 2009.
30. M. S. Sundrud, S. B. Koralov, M. Feuerer et al., "Halofuginone inhibits th17 cell differentiation by activating the amino acid starvation response, " Science, vol. 324, no. 5932, pp. 1334-1338, 2009.
31. M. Brenk, M. Scheler, S. Koch et al., "Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells, " Journal of Immunology, vol. 183, no. 1, pp. 145-154, 2009.
32. H. Xu, G.-X. Zhang, B. Ciric, and A. Rostami, "IDO: a doubleedged sword for TH1/TH2 regulation, " Immunology Letters, vol. 121, no. 1, pp. 1-6, 2008.
33. H. Xu, T. B. Oriss, M. Fei et al., "Indoleamine 2, 3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 18, pp. 6690-6695, 2008.
34. N. T. Nguyen, A. Kimura, T. Nakahamaet al., "Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 19961-19966, 2010.
35. J. M. Ryan, F. Barry, J. M. Murphy, and B. P. Mahon, "Interferon-does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells, " Clinical and Experimental Immunology, vol. 149, no. 2, pp. 353-363, 2007.
36. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, "Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2, " Blood, vol. 111, no. 3, pp. 1327-1333, 2008.
37. L. Pinton, S. Solito, V. Damuzzo et al., "Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression, " Oncotarget, vol. 7, no. 2, pp. 1168-1184, 2015.
38. S. Y. Chon, H. H. Hassanain, and S. L. Gupta, "Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-inducible expression of human indoleamine 2, 3-dioxygenase gene, " The Journal of Biological Chemistry, vol. 271, no. 29, pp. 17247-17252, 1996.
39. W. Dai and S. L. Gupta, "Regulation of indoleamine 2, 3-dioxygenase gene expression in human fibroblasts by interferon-. Upstream control region discriminates between interferon-and interferon-, " Journal of Biological Chemistry, vol. 265, no. 32, pp. 19871-19877, 1990.
40. C. Orabona, P. Puccetti, C. Vacca et al., "Toward the identification of a tolerogenic signature in IDO-competent dendritic cells, " Blood, vol. 107, no. 7, pp. 2846-2854, 2006.
41. H. Yagi, A. Soto-Gutierrez, B. Parekkadan et al., "Mesenchymal stem cells: mechanisms of immunomodulation and homing, " Cell Transplantation, vol. 19, no. 6-7, pp. 667-679, 2010.
42. D. Braun, R. S. Longman, and M. L. Albert, "A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation, " Blood, vol. 106, no. 7, pp. 2375-2381, 2005.
43. M. Rodríguez, E. Domingo, C. Municio et al., "Polarization of the innate immune response by prostaglandin E2: a puzzle of receptors and signals, " Molecular Pharmacology, vol. 85, no. 1, pp. 187-197, 2014.
44. V. Sreeramkumar, M. Fresno, and N. Cuesta, "Prostaglandin E2 and T cells: friends or foes" Immunology & Cell Biology, vol. 90, no. 6, pp. 579-586, 2012.
45. M. Betz and B. S. Fox, "Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines, " Journal of Immunology, vol. 146, no. 1, pp. 108-113, 1991.
46. F. Meyer, K. S. Ramanujam, A. P. Gobert, S. P. James, and K. T. Wilson, "Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori, " The Journal of Immunology, vol. 171, no. 8, pp. 3913-3917, 2003.
47. J. H. Ylöstalo, T. J. Bartosh, K. Coble, and D. J. Prockop, "Human mesenchymal stem/stromal cells cultured as spheroids are selfactivated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype, " StemCells, vol. 30, no. 10, pp. 2283-2296, 2012.
48. T. Khayrullina, J.-H. Yen, H. Jing, and D. Ganea, "In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation ofThl7 cells, " Journal of Immunology, vol. 181, no. 1, pp. 721-735, 2008.
49. C. Yao, D. Sakata, Y. Esaki et al., "Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion, " Nature Medicine, vol. 15, no. 6, pp. 633-640, 2009.
50. R. Tatara, K. Ozaki, Y. Kikuchi et al., "Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation, " Cytotherapy, vol. 13, no. 6, pp. 686-694, 2011.
51. S. Sharma, S.-C. Yang, L. Zhu et al., "Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer, " Cancer Research, vol. 65, no. 12, pp. 5211-5220, 2005.
52. M. Fujita, G. Kohanbash, W. Fellows-Mayle et al., "COX-2 blockade suppresses gliomagenesis by inhibiting myeloidderived suppressor cells, " Cancer Research, vol. 71, no. 7, pp. 2664-2674, 2011.
53. N. Obermajer and P. Kalinski, "Generation of myeloidderived suppressor cells using prostaglandin E2, " Transplantation Research, vol. 1, article 15, 2012.
54. Y. Mao, D. Sarhan, A. Steven, B. Seliger, R. Kiessling, and A. Lundqvist, "Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity, " Clinical Cancer Research, vol. 20, no. 15, pp. 4096-4106, 2014.
55. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses, " Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
56. L. Jarvinen, L. Badri, S. Wettlaufer et al., "Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator, " The Journal of Immunology, vol. 181, no. 6, pp. 4389-4396, 2008.
57. E. Eruslanov, I. Daurkin, J. Ortiz, J. Vieweg, and S. Kusmartsev, "Pivotal advance: tumor-mediated induction of myeloidderived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism inmyeloid cells, " Journal of Leukocyte Biology, vol. 88, no. 5, pp. 839-848, 2010.
58. P. Serafini, "Editorial: PGE2-producing MDSC: a role in tumor progression" Journal of Leukocyte Biology, vol. 88, no. 5, pp. 827-829, 2010.
59. K. English, F. P. Barry, C. P. Field-Corbett, and B. P. Mahon, "IFN-and TNF-differentially regulate immunomodulation by murine mesenchymal stem cells, " Immunology Letters, vol. 110, no. 2, pp. 91-100, 2007.
60. P. C. Rodriguez, D. G. Quiceno, and A. C. Ochoa, "L-arginine availability regulates T-lymphocyte cell-cycle progression, " Blood, vol. 109, no. 4, pp. 1568-1573, 2007.
61. P. C. Rodriguez, A. H. Zea, K. S. Culotta, J. Zabaleta, J. B. Ochoa, and A. C. Ochoa, "Regulation of T cell receptor 3 chain expression by l-arginine, " The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21123-21129, 2002.
62. M. Modolell, B.-S. Choi, R. O. Ryan et al., "Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis, " PLoS Neglected Tropical Diseases, vol. 3, no. 7, article no. e480, 2009.
63. D. R. Herbert, T. Orekov, A. Roloson et al., "Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis, " Journal of Immunology, vol. 184, no. 11, pp. 6438-6446, 2010.
64. K. C. El Kasmi, J. E. Qualls, J. T. Pesce et al., "Toll-like receptorinduced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens, " Nature Immunology, vol. 9, no. 12, pp. 1399-1406, 2008.
65. M. Yang, D. Rangasamy, K. I. Matthaei et al., "Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness, "TheJournal of Immunology, vol. 177, no. 8, pp. 5595-5603, 2006.
66. J. T. Pesce, T. R. Ramalingam, M. M. Mentink-Kane et al., "Arginase-1-expressing macrophages suppress Th2 cytokinedriven inflammation and fibrosis, " PLoS Pathogens, vol. 5, no. 4, pp. 1-15, 2010.
67. P. Serafini, S. Mgebroff, K. Noonan, and I. Borrello, "Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells, " Cancer Research, vol. 68, no. 13, pp. 5439-5449, 2008.
68. J. Chang, S. Thangamani, M. H. Kim, B. Ulrich, S. M. Morris, and C. H. Kim, "Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation, " European Journal of Immunology, vol. 43, no. 4, pp. 967-978, 2013.
69. R. M. Bingisser, P. A. Tilbrook, P. G. Holt, and U. R. Kees, "Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway, " The Journal of Immunology, vol. 160, no. 12, pp. 5729-5734, 1998.
70. A. Mazzoni, V. Bronte, A. Visintin et al., "Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism, " Journal of Immunology, vol. 168, no. 2, pp. 689-695, 2002.
71. O. Harari and J. K. Liao, "Inhibition of MHC II gene transcription by nitric oxide and antioxidants, " Current Pharmaceutical Design, vol. 10, no. 8, pp. 893-898, 2004.
72. A. W. Taylor-Robinson, F. Y. Liew, A. Severn et al., "Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells, " European Journal of Immunology, vol. 24, no. 4, pp. 980-984, 1994.
73. H. Bauer, T. Jung, D. Tsikas, D. O. Stichtenoth, J. C. Frölich, and C. Neumann, "Nitric oxide inhibits the secretion of T-helper 1-andT-helper 2-associated cytokines inactivatedhumanTcells, " Immunology, vol. 90, no. 2, pp. 205-211, 1997.
74. M. Munder, F. Mollinedo, J. Calafat et al., "Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity, " Blood, vol. 105, no. 6, pp. 2549-2556, 2005.
75. S. Gordon, "Alternative activation of macrophages, " Nature Reviews Immunology, vol. 3, no. 1, pp. 23-35, 2003.
76. A. H. Zea, P. C. Rodriguez, M. B. Atkins et al., "Arginaseproducing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion, " Cancer Research, vol. 65, no. 8, pp. 3044-3048, 2005.
77. K. Sato, K. Ozaki, I. Oh et al., "Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells, " Blood, vol. 109, no. 1, pp. 228-234, 2007.
78. B. L. Yen, M.-L. Yen, P.-J. Hsu et al., "Multipotent human mesenchymal stromal cells mediate expansion of myeloidderived suppressor cells via hepatocyte growth factor/c-Met and STAT3, " Stem Cell Reports, vol. 1, no. 2, pp. 139-151, 2013.
79. G. Ren, L. Zhang, X. Zhao et al., "Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide, " Cell Stem Cell, vol. 2, no. 2, pp. 141-150, 2008.
80. X. Han, Q. Yang, L. Lin et al., "Interleukin-17 enhances immunosuppression by mesenchymal stem cells, " Cell Death and Differentiation, vol. 21, no. 11, pp. 1758-1768, 2014.
81. J. E. Talmadge, K. C. Hood, L. C. Zobel, L. R. Shafer, M. Coles, and B. Toth, "Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion, " International Immunopharmacology, vol. 7, no. 2, pp. 140-151, 2007.
82. T. Lu and D. I. Gabrilovich, "Molecular pathways: tumorinfiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment, " Clinical Cancer Research, vol. 18, no. 18, pp. 4877-4882, 2012.
83. B. Molon, S. Ugel, F. Del Pozzo et al., "Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells, " The Journal of ExperimentalMedicine, vol. 208, no. 10, pp. 1949-1962, 2011.
84. S.-R. Yang, J.-R. Park, and K.-S. Kang, "Reactive oxygen species in mesenchymal stem cell aging: implication to lung diseases, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 486263, 11 pages, 2015.
85. S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, "Transforming growth factor-and the immune response: implications for anticancer therapy, " Clinical Cancer Research, vol. 13, no. 18, pp. 5262-5270, 2007.
86. V. L. Heath, E. E. Murphy, C. Crain, M. G. Tomlinson, and A. O'Garra, "TGF-1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression, " European Journal of Immunology, vol. 30, no. 9, pp. 2639-2649, 2000.
87. L. Gorelik, S. Constant, and R. A. Flavell, "Mechanism of transforming growth factor-induced inhibition of T helper type 1 differentiation, " The Journal of Experimental Medicine, vol. 195, no. 11, pp. 1499-1505, 2002.
88. C. M. Evans and R. G. Jenner, "Transcription factor interplay in T helper cell differentiation, " Briefings in Functional Genomics, vol. 12, no. 6, pp. 499-511, 2013.
89. C. Xu, P. Yu, X. Han et al., "TGF-promotes immune responses in the presence of mesenchymal stem cells, " The Journal of Immunology, vol. 192, no. 1, pp. 103-109, 2014.
90. S. M. Melief, E. Schrama, M. H. Brugman et al., "Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward antiinflammatory macrophages, " Stem Cells, vol. 31, no. 9, pp. 1980-1991, 2013.
91. A. U. Engela, C. C. Baan, F. J. M. F. Dor, W. Weimar, and M. J. Hoogduijn, "On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation, " Frontiers in Immunology, vol. 3, article 126, pp. 1-9, 2012.
92. S. Fichtner-Feigl, M. Terabe, A. Kitani et al., "Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-2, " Cancer Research, vol. 68, no. 9, pp. 3467-3475, 2008.
93. K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. O'Garra, "Interleukin-10 and the interleukin-10 receptor, " Annual Review of Immunology, vol. 19, pp. 683-765, 2001.
94. L. D. Hazlett, X. Jiang, and S. A. Mcclellan, "IL-10 function, regulation, and in bacterial keratitis, " Journal of Ocular Pharmacology andTherapeutics, vol. 30, no. 5, pp. 373-380, 2014.
95. A. Chaudhry, R. M. Samstein, P. Treuting et al., "Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation, " Immunity, vol. 34, no. 4, pp. 566-578, 2011.
96. O. Akbari, R. H. DeKruyff, and D. T. Umetsu, "Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen, " Nature Immunology, vol. 2, no. 8, pp. 725-731, 2001.
97. M. T. Zdrenghea, H. Makrinioti, A. Muresan, S. L. Johnston, and L. A. Stanciu, "The role of macrophage IL-10/innate IFN interplay during virus-induced asthma, " Reviews in Medical Virology, vol. 25, no. 1, pp. 33-49, 2015.
98. M. R. Walter, "The molecular basis of IL-10 function: from receptor structure to the onset of signaling, " Current Topics in Microbiology and Immunology, vol. 380, pp. 191-212, 2014.
99. D. G. Brooks, K. B. Walsh, H. Elsaesser, and M. B. A. Oldstone, "IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 7, pp. 3018-3023, 2010.
100. M. Saraiva and A. O'Garra, "The regulation of IL-10 production by immune cells, " Nature Reviews Immunology, vol. 10, no. 3, pp. 170-181, 2010.
101. H. Harizi and N. Gualde, "Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators, " Cellular and Molecular Immunology, vol. 3, no. 4, pp. 271-277, 2006.
102. M. Benkhoucha, M.-L. Santiago-Raber, G. Schneiter et al., "Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6424-6429, 2010.
103. K. Okunishi, M. Dohi, K. Fujio et al., "Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice, " Journal of Immunology, vol. 179, no. 8, pp. 5504-5513, 2007.
104. P.-M. Chen, K.-J. Liu, P.-J. Hsu et al., "Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2, " Journal of Leukocyte Biology, vol. 96, no. 2, pp. 295-303, 2014.
105. M. Madrigal, K. S. Rao, and N. H. Riordan, "A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods, " Journal of Translational Medicine, vol. 12, article 260, 2014.
106. B. Toh, X. Wang, J. Keeble et al., "Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor, " PLoS Biology, vol. 9, no. 9, Article ID e1001162, 2011.
107. J. LeMaoult, K. Zafaranloo, C. Le Banff, and E. D. Carosella, "HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells, " The FASEB Journal, vol. 19, no. 6, pp. 662-664, 2005.
108. E. D. Carosella, S. Gregori, and J. LeMaoult, "The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells, " Blood, vol. 118, no. 25, pp. 6499-6505, 2011.
109. G. Curigliano, C. Criscitiello, L. Gelao, and A. Goldhirsch, "Molecular pathways: human leukocyte antigen G(HLA-G), " Clinical Cancer Research, vol. 19, no. 20, pp. 5564-5571, 2013.
110. F. Morandi, E. Ferretti, P. Bocca, I. Prigione, L. Raffaghello, and V. Pistoia, "A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis, " PLoSONE, vol. 5, no. 7, Article IDe11763, 2010.
111. S. Agaugué, E. D. Carosella, and N. Rouas-Freiss, "Role of HLA-G in tumor escape through expansion ofmyeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17, " Blood, vol. 117, no. 26, pp. 7021-7031, 2011.
112. Z. Selmani, A. Naji, I. Zidi et al., "Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte andnatural killer functionand to induce CD4+CD25highFOXP3+ regulatory T cells, " STEM CELLS, vol. 26, no. 1, pp. 212-222, 2008.
113. A. Nasef, N. Mathieu, A. Chapel et al., "Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G, " Transplantation, vol. 84, no. 2, pp. 231-237, 2007.
114. F. Montespan, F. Deschaseaux, L. Sensébé, E. D. Carosella, and N. Rouas-Freiss, "Osteodifferentiated mesenchymal stem cells from bone marrow and adipose tissue express HLA-G and display immunomodulatory properties inHla-mismatched settings: implications in bone repair therapy, " Journal of Immunology Research, vol. 2014, Article ID 230346, 10 pages, 2014.
115. K. Kapasi, S. E. Albert, S.-M. Yie, N. Zavazava, and C. L. Librach, "HLA-G has a concentration-dependent effect on the generation of an allo-CTL response, " Immunology, vol. 101, no. 2, pp. 191-200, 2000.
116. E. Kerkelä, A. Laitinen, J. Räbinä et al., "Adenosinergicimmunosuppression by human mesenchymal stromal cells (MSCs) requires co-operation with T cells, " Stem Cells, vol. 34, no. 3, pp. 781-790, 2016.
117. M. Chen, W. Su, X. Lin et al., "Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collageninduced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation, " Arthritis and Rheumatism, vol. 65, no. 5, pp. 1181-1193, 2013.
118. S. Ryzhov, S. V. Novitskiy, A. E. Goldstein et al., "Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells, " Journal of Immunology, vol. 187, no. 11, pp. 6120-6129, 2011.
119. C. Ye, Z. Geng, D. Dominguez et al., "Targeting ornithine decarboxylase by-difluoromethylornithine inhibits tumor growth by impairing myeloid-derived suppressor cells, " The Journal of Immunology, vol. 196, no. 2, pp. 915-923, 2016.
120. S. Thiemann, J. H. Man, M. H. Chang, B. Lee, and L. G. Baum, "Galectin-1 regulates tissue exit of specific dendritic cell populations, "The Journal of Biological Chemistry, vol. 290, no. 37, pp. 22662-22667, 2015.
121. M. A. Toscano, G. A. Bianco, J. M. Ilarregui et al., "Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death, " Nature Immunology, vol. 8, no. 8, pp. 825-834, 2007.
122. F. Cedeno-Laurent, M. Opperman, S. R. Barthel, V. K. Kuchroo, and C. J. Dimitroff, "Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression, " The Journal of Immunology, vol. 188, no. 7, pp. 3127-3137, 2012.
123. C. Ungerer, P. Quade-Lyssy, H. H. Radeke et al., "Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations, " Stem Cells and Development, vol. 23, no. 7, pp. 755-766, 2014.
124. T. Verschuere, J. Toelen, W. Maes et al., "Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity, " International Journal of Cancer, vol. 134, no. 4, pp. 873-884, 2014.
125. N. Che, X. Li, L. Zhang et al., "Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCl2 expression, " Journal of Immunology, vol. 193, no. 10, pp. 5306-5314, 2014.
126. M. Rafei, P. M. Campeau, A. Aguilar-Mahecha et al., "Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner, " The Journal of Immunology, vol. 182, no. 10, pp. 5994-6002, 2009.
127. M. Hale, F. Itani, C. M. Buchta, G. Wald, M. Bing, and L. A. Norian, "Obesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2, " PLoS ONE, vol. 10, no. 3, Article IDe0118784, 2015.
128. A. Augello, R. Tasso, S. M. Negrini et al., "Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway, " European Journal of Immunology, vol. 35, no. 5, pp. 1482-1490, 2005.
129. H. Sheng, Y. Wang, Y. Jin et al., "A critical role of IFN in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1, " Cell Research, vol. 18, no. 8, pp. 846-857, 2008.
130. M. E. Groh, B. Maitra, E. Szekely, and O. N. Koç, "Human mesenchymal stem cells requiremonocyte-mediated activation to suppress alloreactive T cells, " Experimental Hematology, vol. 33, no. 8, pp. 928-934, 2005.
131. S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi, "Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells, " Blood, vol. 105, no. 7, pp. 2821-2827, 2005.
132. R. Nagaya, M. Mizuno-Kamiya, E. Takayama et al., "Mechanisms of the immunosuppressive effects of mouse adipose tissue-derived mesenchymal stromal cells on mouse alloreactively stimulated spleen cells, " Experimental and Therapeutic Medicine, vol. 7, no. 1, pp. 17-22, 2013.
133. K. Le Blanc, L. Tammik, B. Sundberg, S. E. Haynesworth, and O. Ringdén, "Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures andmitogenic responses independently of the major histocompatibility complex, " Scandinavian Journal of Immunology, vol. 57, no. 1, pp. 11-20, 2003.
134. E. Schurgers, H. Kelchtermans, T. Mitera, L. Geboes, and P. Matthys, "Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis, " Arthritis Research & Therapy, vol. 12, no. 1, article R31, pp. 1-11, 2010.
135. D. Wang, X. Feng, L. Lu et al., "A CD8 T cell/indoleamine 2, 3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus, " Arthritis and Rheumatology, vol. 66, no. 8, pp. 2234-2245, 2014.
136. P. Luz-Crawford, M. Kurte, J. Bravo-Alegría et al., "Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells, " Stem Cell Research and Therapy, vol. 4, no. 3, article 65, 2013.
137. R. Chinnadurai, I. B. Copland, S. R. Patel, and J. Galipeau, "IDO-independent suppression of T cell effector function by IFN-licensed human mesenchymal stromal cells, "TheJournal of Immunology, vol. 192, no. 4, pp. 1491-1501, 2014.
138. M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferon-in the immunomodulatory activity of human bone marrow mesenchymal stem cells, " STEM CELLS, vol. 24, no. 2, pp. 386-398, 2006.
139. R. Haddad and F. Saldanha-Araujo, "Mechanisms of T-cell immunosuppression bymesenchymal stromal cells: what do we know so far" BioMed Research International, vol. 2014, Article ID 216806, 14 pages, 2014.
140. S. Ghannam, J. Pène, G. Moquet-Torcy, C. Jorgensen, and H. Yssel, "Mesenchymal stem cells inhibit human Th17 celldifferentiation and function and induce a T regulatory cell phenotype, " Journal of Immunology, vol. 185, no. 1, pp. 302-312, 2010.
141. M. M. Duffy, J. Pindjakova, S. A. Hanley et al., "Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor, " European Journal of Immunology, vol. 41, no. 10, pp. 2840-2851, 2011.
142. X. Qu, X. Liu, K. Cheng, R. Yang, and R. C. H. Zhao, "Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion, " Experimental Hematology, vol. 40, no. 9, pp. 761-770, 2012.
143. F. Benvenuto, S. Ferrari, E. Gerdoni et al., "Human mesenchymal stem cells promote survival of T cells in a quiescent state, " STEM CELLS, vol. 25, no. 7, pp. 1753-1760, 2007.
144. K.-S. Cho, Y.-W. Kim, M. J. Kang, H.-Y. Park, S.-L. Hong, and H.-J. Roh, "Immunomodulatory effect of mesenchymal stem cells on T lymphocyte and cytokine expression in nasal polyps, " Otolaryngology-Head and Neck Surgery, vol. 150, no. 6, pp. 1062-1070, 2014.
145. A. Eljaafari, M.-L. Tartelin, H. Aissaoui et al., "Bone marrowderived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis, " Arthritis and Rheumatism, vol. 64, no. 7, pp. 2147-2157, 2012.
146. S. Strober, "Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships, " Annual Review of Immunology, vol. 2, pp. 219-237, 1984.
147. R. B. Schwadron, D. M. Gandour, and S. Strober, "Cloned natural suppressor cell lines derived from the spleens of neonatal mice, "The Journal of Experimental Medicine, vol. 162, no. 1, pp. 297-310, 1985.
148. S. A. Kusmartsev, Y. Li, and S.-H. Chen, "Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation, " The Journal of Immunology, vol. 165, no. 2, pp. 779-785, 2000.
149. J.-I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich, "Subsets ofmyeloid-derived suppressor cells in tumor-bearing mice, "The Journal of Immunology, vol. 181, no. 8, pp. 5791-5802, 2008.
150. S. K. Bunt, V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg, "Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4, " Journal of Leukocyte Biology, vol. 85, no. 6, pp. 996-1004, 2009.
151. A. M. Lesokhin, T. M. Hohl, S. Kitano et al., "Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment, " Cancer Research, vol. 72, no. 4, pp. 876-886, 2012.
152. Y. Iwata, K. Furuichi, K. Kitagawa et al., "Involvement ofCD11b+ GR-1low cells in autoimmune disorder in MRL-Fas lpr mouse, " Clinical and Experimental Nephrology, vol. 14, no. 5, pp. 411-417, 2010.
153. P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg, "Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response, " The Journal of Immunology, vol. 179, no. 2, pp. 977-983, 2007.
154. J. J. Messmann, T. Reisser, F. Leithäuser, M. B. Lutz, K.-M. Debatin, and G. Strauss, "In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity, " Blood, vol. 126, no. 9, pp. 1138-1148, 2015.
155. J. Liao, X. Wang, Y. Bi et al., "Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide, " Journal of Leukocyte Biology, vol. 96, no. 5, pp. 675-684, 2014.
156. J. Gao, Y. Wu, Z. Su et al., "Infiltration of alternatively activated macrophages in cancer tissue is associated withMDSC and Th2 polarization in patients with esophageal cancer, " PLoSONE, vol. 9, no. 8, article e104453, 2014.
157. S. Chatterjee, S. Das, P. Chakraborty, A. Manna, M. Chatterjee, and S. K. Choudhuri, "Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from nä?ve CD4+ T cells, " Immunobiology, vol. 218, no. 5, pp. 718-724, 2013.
158. J. L. Bowen and J. K. Olson, "Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease, " Journal of Immunology, vol. 183, no. 11, pp. 6971-6980, 2009.
159. A. Zoso, E. M. C. Mazza, S. Bicciato et al., "Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion, " European Journal of Immunology, vol. 44, no. 11, pp. 3307-3319, 2014.
160. B. Huang, P.-Y. Pan, Q. Li et al., "Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T-cell anergy in tumor-bearing host, " Cancer Research, vol. 66, no. 2, pp. 1123-1131, 2006.
161. P.-Y. Pan, G. Ma, K. J. Weber et al., "Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer, " Cancer Research, vol. 70, no. 1, pp. 99-108, 2010.
162. H.-S. Chou, C.-C. Hsieh, R. Charles et al., "Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells, " Transplantation, vol. 93, no. 3, pp. 272-282, 2012.
163. X.-X. Jiang, Y. Zhang, B. Liu et al., "Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells, " Blood, vol. 105, no. 10, pp. 4120-4126, 2005.
164. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe, "Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells, " The Journal of Immunology, vol. 177, no. 4, pp. 2080-2087, 2006.
165. F. Djouad, L.-M. Charbonnier, C. Bouffi et al., "Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependentmechanism, " StemCells, vol. 25, no. 8, pp. 2025-2032, 2007.
166. G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta, "MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2, " Blood, vol. 113, no. 26, pp. 6576-6583, 2009.
167. S. M. Melief, S. B. Geutskens, W. E. Fibbe, and H. Roelofs, "Multipotent stromal cells skew monocytes towards an antiinflammatory interleukin-10-producing phenotype by production of interleukin-6, " Haematologica, vol. 98, no. 6, pp. 888-895, 2013.
168. W.-H. Liu, J.-J. Liu, J. Wu et al., "Novelmechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway, " PLoS ONE, vol. 8, no. 1, Article ID e55487, 13 pages, 2013.
169. Y. Liu, Z. Yin, R. Zhang et al., "MSCs inhibit bone marrowderived DC maturation and function through the release of TSG-6, " Biochemical and Biophysical Research Communications, vol. 450, no. 4, pp. 1409-1415, 2014.
170. Y. Zhang, W. Cai, Q. Huang et al., "Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells, " Hepatology, vol. 59, no. 2, pp. 671-682, 2014.
171. X. Liu, X. Qu, Y. Chen et al., "Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation, " The Journal of Immunology, vol. 189, no. 3, pp. 1182-1192, 2012.
172. S. Rutella, G. Bonanno, A. Procoli et al., "Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features, " Blood, vol. 108, no. 1, pp. 218-227, 2006.
173. C. J. Greenhill, S. Rose-John, R. Lissilaa et al., "IL-6 transsignaling modulates TLR4-dependent inflammatory responses via STAT3, " The Journal of Immunology, vol. 186, no. 2, pp. 1199-1208, 2011.
174. H. Zhang, H. Hu, N. Greeley et al., "STAT3 restrains RANKand TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13, " Nature Communications, vol. 5, article 6798, 2014.
175. Y.-P. Li, S. Paczesny, E. Lauret et al., "Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway, " Journal of Immunology, vol. 180, no. 3, pp. 1598-1608, 2008.
176. A. Aldinucci, L. Rizzetto, L. Pieri et al., "Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation, " The Journal of Immunology, vol. 185, no. 9, pp. 5102-5110, 2010.
177. S. Chiesa, S. Morbelli, S. Morando et al., "Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 42, pp. 17384-17389, 2011.
178. S. K. Biswas and A. Mantovani, "Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, " Nature Immunology, vol. 11, no. 10, pp. 889-896, 2010.
179. S. Gao, F. Mao, B. Zhang et al., "Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-B and signal transducer and activator of transcription 3 pathways, " Experimental Biology and Medicine, vol. 239, no. 3, pp. 366-375, 2014.
180. J. Kim and P. Hematti, "Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages, " Experimental Hematology, vol. 37, no. 12, pp. 1445-1453, 2009.
181. K. Németh, A. Leelahavanichkul, P. S. T. Yuen et al., "Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production, " Nature Medicine, vol. 15, no. 1, pp. 42-49, 2009.
182. H. Choi, R. H. Lee, N. Bazhanov, J. Y. Oh, and D. J. Prockop, "Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-B signaling in resident macrophages, " Blood, vol. 118, no. 2, pp. 330-338, 2011.
183. M. François, R. Romieu-Mourez, M. Li, and J. Galipeau, "Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation, " Molecular Therapy, vol. 20, no. 1, pp. 187-195, 2012.
184. Q.-Z. Zhang, W.-R. Su, S.-H. Shi et al., "Human gingiva-derived mesenchymal stem cells elicit polarization of M2 macrophages and enhance cutaneous wound healing, " Stem Cells, vol. 28, no. 10, pp. 1856-1868, 2010.
185. T. Maron-Gutierrez, J. D. Silva, K. D. Asensi et al., "Effects of mesenchymal stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice, " Critical Care Medicine, vol. 41, no. 11, pp. e319-e333, 2013.
186. L. Ionescu, R. N. Byrne, T. van Haaften et al., "Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action, " The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 303, no. 11, pp. L967-L977, 2012.
187. I. Poschke, Y. Mao, L. Adamson, F. Salazar-Onfray, G. Masucci, and R. Kiessling, "Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines, " Cancer Immunology, Immunotherapy, vol. 61, no. 6, pp. 827-838, 2012.
188. C.-E. Hu, J. Gan, R.-D. Zhang, Y.-R. Cheng, and G.-J. Huang, "Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function, " Scandinavian Journal of Gastroenterology, vol. 46, no. 2, pp. 156-164, 2011.
189. A. Corcione, F. Benvenuto, E. Ferretti et al., "Human mesenchymal stem cells modulate B-cell functions, " Blood, vol. 107, no. 1, pp. 367-372, 2006.
190. M. Franquesa, F. K. Mensah, R. Huizinga et al., "Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells, " Stem Cells, vol. 33, no. 3, pp. 880-891, 2015.
191. M. M. Rosado, M. E. Bernardo, M. Scarsella et al., "Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells, " Stem Cells and Development, vol. 24, no. 1, pp. 93-103, 2015.
192. E. Traggiai, S. Volpi, F. Schena et al., "Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients, " STEM CELLS, vol. 26, no. 2, pp. 562-569, 2008.
193. I. Rasmusson, K. Le Blanc, B. Sundberg, and O. Ringdén, "Mesenchymal stem cells stimulate antibody secretion in human B cells, " Scandinavian Journal of Immunology, vol. 65, no. 4, pp. 336-343, 2007.
194. Y. Qin, Z. Zhou, F. Zhang et al., "Induction of regulatory Bcells by mesenchymal stem cells is affected by SDF-1-CXCR7, " Cellular Physiology and Biochemistry, vol. 37, no. 1, pp. 117-130, 2015.
195. Y. Peng, X. Chen, Q. Liu et al., "Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10, " Leukemia, vol. 29, no. 3, pp. 636-646, 2015.
196. S. Asari, S. Itakura, K. Ferreri et al., "Mesenchymal stem cells suppress B-cell terminal differentiation, " Experimental Hematology, vol. 37, no. 5, pp. 604-615, 2009.
197. M. A. O'Connor, W. W. Fu, K. A. Green, and W. R. Green, "Subpopulations of M-MDSCs from mice infected by an immunodeficiency-causing retrovirus and their differential suppression of T-vs B-cell responses, " Virology, vol. 485, pp. 263-273, 2015.
198. K. A. Green, L. Wang, R. J. Noelle, and W. R. Greena, "Selective involvement of the checkpoint regulator VISTA in suppression of B-cell, but not T-cell, responsiveness by monocytic myeloid-derived suppressor cells from mice infected with an immunodeficiency-causing retrovirus, " Journal of Virology, vol. 89, no. 18, pp. 9693-9698, 2015.
199. D. E. Kennedy andK. L. Knight, "Inhibition of B lymphopoiesis by adipocytes and IL-1-producing myeloid-derived suppressor cells, " Journal of Immunology, vol. 195, no. 6, pp. 2666-2674, 2015.
200. K. R. Crook, M. Jin, M. F. Weeks et al., "Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease, " Journal of Leukocyte Biology, vol. 97, no. 3, pp. 573-582, 2015.
201. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, "Interactions between human mesenchymal stem cells and natural killer cells, " Stem Cells, vol. 24, no. 1, pp. 74-85, 2006.
202. D. Chatterjee, D. M. Tufa, H. Baehre, R. Hass, R. E. Schmidt, and R. Jacobs, "Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells, " Blood, vol. 123, no. 4, pp. 594-595, 2014.
203. C. C. Goh, K. M. Roggerson, H. C. Lee, L. Golden-Mason, H. R. Rosen, and Y. S. Hahn, "Hepatitis C virus-induced myeloidderived suppressor cells suppress NK cell IFN-production by altering cellular metabolism via arginase-1, " The Journal of Immunology, vol. 196, no. 5, pp. 2283-2292, 2016.
204. J. L. Wong, N. Obermajer, K. Odunsi, R. P. Edwards, and P. Kalinski, "Synergistic COX2 induction by IFN and TNF selflimits type-1 immunity in the human tumor microenvironment, " Cancer Immunology Research, vol. 4, no. 4, pp. 303-311, 2016.
205. O. Draghiciu, J. Lubbers, H. W. Nijman, and T. Daemen, "Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy, " OncoImmunology, vol. 4, no. 1, Article ID 954829, 11 pages, 2015.
206. J. Zhu, X. Huang, and Y. Yang, "Myeloid-derived suppressor cells regulate natural killer cell response to adenovirusmediated gene transfer, " The Journal of Virology, vol. 86, no. 24, pp. 13689-13696, 2012.
207. L. Raffaghello, G. Bianchi, M. Bertolotto et al., "Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche, " Stem Cells, vol. 26, no. 1, pp. 151-162, 2008.
208. M. A. Cassatella, F. Mosna, A. Micheletti et al., "Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils, " STEM CELLS, vol. 29, no. 6, pp. 1001-1011, 2011.
209. S. Brandau, M. Jakob, H. Hemeda et al., "Tissue-residentmesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge, " Journal of Leukocyte Biology, vol. 88, no. 5, pp. 1005-1015, 2010.
210. S. R. R. Hall, K. Tsoyi, B. Ith et al., "Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils, " Stem Cells, vol. 31, no. 2, pp. 397-407, 2013.
211. S.-C. Hsu, L.-T. Wang, C.-L. Yao et al., "Mesenchymal stem cells promote neutrophil activation by inducing IL-17 production in CD4+ CD45RO+ T cells, " Immunobiology, vol. 218, no. 1, pp. 90-95, 2013.
212. S. L. Poe, M. Arora, T. B. Oriss et al., "STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia, " Mucosal Immunology, vol. 6, no. 1, pp. 189-199, 2013.
213. A. Ray, K. Chakraborty, and P. Ray, "Immunosuppressive MDSCS induced by TLR signaling during infection and role in resolution of inflammation, " Frontiers in Cellular and Infection Microbiology, vol. 3, article 52, 2013.
214. H. W. Chen, H.-Y. Chen, L.-T. Wang et al., "Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines, " The Journal of Immunology, vol. 190, no. 10, pp. 5065-5077, 2013.
215. R. S. Waterman, S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt, "A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype, " PLoS ONE, vol. 5, no. 4, Article ID e10088, 2010.
216. R. Okamoto and M. Watanabe, "Investigating cell therapy for inflammatory bowel disease, " Expert Opinion on Biological Therapy, 2016.
217. A. Cras, D. Farge, T. Carmoi, J.-J. Lataillade, D. D. Wang, and L. Sun, "Update onmesenchymal stem cell-based therapy in lupus and scleroderma, " Arthritis Research & Therapy, vol. 17, article 301, 2015.
218. A. Dulamea, "Mesenchymal stem cells in multiple sclerosis- translation to clinical trials, " Journal ofMedicine and Life, vol. 8, no. 1, pp. 24-27, 2015.
219. S. Llufriu, M. Sepúlveda, Y. Blanco et al., "Randomized placebocontrolled phase II trial of autologous mesenchymal stem cells in multiple sclerosis, " PLoS ONE, vol. 9, no. 12, Article ID e113936, 2014.
220. M. Rizk, M. Monaghan, R. Shorr, N. Kekre, C. N. Bredeson, and D. S. Allan, "Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence, " Biology of Blood and Marrow Transplantation, 2016.
221. C. Chen and J. Hou, "Mesenchymal stem cell-based therapy in kidney transplantation, " Stem Cell Research & Therapy, vol. 7, no. 1, p. 16, 2016.
222. M. T. Cerqueira, R. P. Pirraco, and A. P. Marques, "Stem cells in skin wound healing: are we there yet" Advances in Wound Care, vol. 5, no. 4, pp. 164-175, 2016.
223. F. Ezquer, "Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease, " World Journal of Gastroenterology, vol. 22, no. 1, p. 24, 2016.
224. S. Wakitani, T. Okabe, S. Horibe et al., "Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months, " Journal of Tissue Engineering and Regenerative Medicine, vol. 5, no. 2, pp. 146-150, 2011.
225. J. M. Hare, J. H. Traverse, T. D. Henry et al., "A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction, " Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277-2286, 2009.
226. U. B. Savukinas, S. R. Enes, A. A. Sjöland, and G. Westergren-Thorsson, "The bystander effect: MSC-mediated lung repair, " Stem Cells, 2016.
227. M. Otero-Viñas and V. Falanga, "Mesenchymal stem cells in chronic wounds: the spectrum frombasic to advanced therapy, " Advances inWound Care, vol. 5, no. 4, pp. 149-163, 2016.
228. D. Di Mitri, A. Toso, and A. Alimonti, "Molecular pathways: targeting tumor-infiltrating myeloid-derived suppressor cells for cancer therapy, " Clinical Cancer Research, vol. 21, no. 14, pp. 3108-3112, 2015.
229. J. Markowitz, R. Wesolowski, T. Papenfuss, T. R. Brooks, and W. E. Carson III, "Myeloid-derived suppressor cells in breast cancer, " Breast Cancer Research and Treatment, vol. 140, no. 1, pp. 13-21, 2013.
230. K. A. Stoermer, A. Burrack, L. Oko et al., "Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus, " Journal of Immunology, vol. 189, no. 8, pp. 4047-4059, 2012.
231. M. Arora, S. L. Poe, T. B. Oriss et al., "TLR4/MyD88-induced CD11b+ Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung, " Mucosal Immunology, vol. 3, no. 6, pp. 578-593, 2010.